1. |
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822):1245-1255.
|
2. |
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
|
3. |
Lu W, Dong J, Huang Z, et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma under-going curative resection:Okuda, CLIP, TNM and CUPI. J Gastroen-terol Hepatol, 2008, 23(12):1874-1878.
|
4. |
王君哲, 牟君成, 范慧, 等.血清肿瘤相关物质检测在恶性肿瘤诊断中的应用价值.重庆医学, 2010, 39(11):1418-1419.
|
5. |
陈芳华, 骆曦, 饶万楷.恶性肿瘤特异性生长因子对恶性肿瘤的诊断价值.国际检验医学杂志, 2011, 32(11):1183-1184, 1186.
|
6. |
周琦, 张琼, 魏来.血清甲胎蛋白、肿瘤相关物质和癌胚抗原对原发性肝癌的鉴别诊断.世界华人消化杂志, 2010, 18(18):1936-1939.
|
7. |
康从利, 徐日, 徐风亮, 等.血清肿瘤标志物的联合动态检测在原发性肝癌诊断中的价值.肿瘤研究与临床, 2014, 26(8):531-534, 538.
|
8. |
赵建军, 阎涛, 黄振, 等.中国肝细胞癌患者最佳分期系统探讨.中华医学杂志, 2014, 94(12):903-907.
|
9. |
Wang G, Qin Y, Zhang J, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci, 2014, 15(6):9546-9565.
|
10. |
Chen Y, Gao SG, Chen JM, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2014 Dec 9.[Epub ahead of print].
|
11. |
孟冬娅, 胡晓芳, 高洪福, 等.检测血清VEGF、CEA、TSGF在肿瘤中的临床意义.中国现代医学杂志, 2004, 14(1):117-118.
|
12. |
原晓勇, 吴斌.血清TSGF在乳腺癌中的研究现状.现代临床医学, 2011, 37(2):83-84.
|
13. |
Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommenda-tions for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the American Society of Clinical Onco-logy. J Clin Oncol, 2001, 19(6):1865-1878.
|
14. |
王建俊, 王金鹏.血清TSGF和CA199联检对肝硬化的诊断价值的研究.医学检验与临床, 2011, 22(4):18-19.
|
15. |
Karaman B, Battal B, Sari S, et al. Hepatocellular carcinoma review:current treatment, and evidence-based medicine. World J Gastroen-terol, 2014, 20(47):18059-18060.
|